Inhibition and reversal of a TGF-β1 induced myofibroblast phenotype by adipose tissue-derived paracrine factors.


Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 29 03 2024
accepted: 27 05 2024
medline: 13 6 2024
pubmed: 13 6 2024
entrez: 12 6 2024
Statut: epublish

Résumé

Hypertrophic scarring results from myofibroblast differentiation and persistence during wound healing. Currently no effective treatment for hypertrophic scarring exists however, autologous fat grafting has been shown to improve scar elasticity, appearance, and function. The aim of this study was to understand how paracrine factors from adipose tissues and adipose-derived stromal cells (ADSC) affect fibroblast to myofibroblast differentiation. The transforming growth factor-β1 (TGF-β1) induced model of myofibroblast differentiation was used to test the effect of conditioned media from adipose tissue, ADSC or lipid on the proportion of fibroblasts and myofibroblasts. Adipose tissue conditioned media inhibited the differentiation of fibroblasts to myofibroblasts but this inhibition was not observed following treatment with ADSC or lipid conditioned media. Hepatocyte growth factor (HGF) was readily detected in the conditioned medium from adipose tissue but not ADSC. Cells treated with HGF, or fortinib to block HGF, demonstrated that HGF was not responsible for the inhibition of myofibroblast differentiation. Conditioned media from adipose tissue was shown to reduce the proportion of myofibroblasts when added to fibroblasts previously treated with TGF-β1, however, conditioned media treatment was unable to significantly reduce the proportion of myofibroblasts in cell populations isolated from scar tissue. Cultured ADSC or adipocytes have been the focus of most studies, however, this work highlights the importance of considering whole adipose tissue to further our understanding of fat grafting. This study supports the use of autologous fat grafts for scar treatment and highlights the need for further investigation to determine the mechanism.

Sections du résumé

BACKGROUND BACKGROUND
Hypertrophic scarring results from myofibroblast differentiation and persistence during wound healing. Currently no effective treatment for hypertrophic scarring exists however, autologous fat grafting has been shown to improve scar elasticity, appearance, and function. The aim of this study was to understand how paracrine factors from adipose tissues and adipose-derived stromal cells (ADSC) affect fibroblast to myofibroblast differentiation.
METHODS METHODS
The transforming growth factor-β1 (TGF-β1) induced model of myofibroblast differentiation was used to test the effect of conditioned media from adipose tissue, ADSC or lipid on the proportion of fibroblasts and myofibroblasts.
RESULTS RESULTS
Adipose tissue conditioned media inhibited the differentiation of fibroblasts to myofibroblasts but this inhibition was not observed following treatment with ADSC or lipid conditioned media. Hepatocyte growth factor (HGF) was readily detected in the conditioned medium from adipose tissue but not ADSC. Cells treated with HGF, or fortinib to block HGF, demonstrated that HGF was not responsible for the inhibition of myofibroblast differentiation. Conditioned media from adipose tissue was shown to reduce the proportion of myofibroblasts when added to fibroblasts previously treated with TGF-β1, however, conditioned media treatment was unable to significantly reduce the proportion of myofibroblasts in cell populations isolated from scar tissue.
CONCLUSIONS CONCLUSIONS
Cultured ADSC or adipocytes have been the focus of most studies, however, this work highlights the importance of considering whole adipose tissue to further our understanding of fat grafting. This study supports the use of autologous fat grafts for scar treatment and highlights the need for further investigation to determine the mechanism.

Identifiants

pubmed: 38867276
doi: 10.1186/s13287-024-03776-3
pii: 10.1186/s13287-024-03776-3
doi:

Substances chimiques

Transforming Growth Factor beta1 0
Culture Media, Conditioned 0
Hepatocyte Growth Factor 67256-21-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

166

Subventions

Organisme : EPSRC Doctoral Training Programme Scholarship
ID : EP/R513313/1

Informations de copyright

© 2024. The Author(s).

Références

Marshall CD, Hu MS, Leavitt T, Barnes LA, Lorenz HP, Longaker MT. Cutaneous scarring: basic science, current treatments, and future directions. Adv Wound Care (New Rochelle). 2018;7(2):29–45.
pubmed: 29392092 doi: 10.1089/wound.2016.0696
Van Baar ME, Essink-Bot ML, Oen IMMH, Dokter J, Boxma H, Van Beeck EF. Functional outcome after burns: a review. Burns. 2006;32(1):1–9.
pubmed: 16376020 doi: 10.1016/j.burns.2005.08.007
Hoogewerf CJ, van Baar ME, Middelkoop E, van Loey NE. Impact of facial burns: relationship between depressive symptoms, self-esteem and scar severity. Gen Hosp Psychiatry. 2014;36(3):271–6.
pubmed: 24417954 doi: 10.1016/j.genhosppsych.2013.12.001
Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg. 2006;8(6):362–8.
pubmed: 17116782 doi: 10.1001/archfaci.8.6.362
Shockley WW. Scar revision techniques: Z-plasty, W-plasty, and geometric broken line closure. Facial Plast Surg Clin N Am. 2011;19(3):455–63.
doi: 10.1016/j.fsc.2011.06.002
Klinger M, Marazzi M, Vigo D, Torre M. Fat injection for cases of severe burn outcomes: a new perspective of scar remodeling and reduction. Aesthet Plast Surg. 2008;32(3):465–9.
doi: 10.1007/s00266-008-9122-1
Rigotti G, Marchi A, Galiè M, Baroni G, Benati D, Krampera M, Pasini A, Sbarbati A. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007;119(5):1409–22.
pubmed: 17415234 doi: 10.1097/01.prs.0000256047.47909.71
Eto H, Suga H, Matsumoto D, Inoue K, Aoi N, Kato H, Araki J, Yoshimura K. Characterization of structure and cellular components of aspirated and excised adipose tissue. Plast Reconstr Surg. 2009;124(4):1087–97.
pubmed: 19935292 doi: 10.1097/PRS.0b013e3181b5a3f1
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–28.
pubmed: 11304456 doi: 10.1089/107632701300062859
Spiekman M, van Dongen JA, Willemsen JC, Hoppe DL, van der Lei B, Harmsen MC. The power of fat and its adipose-derived stromal cells: emerging concepts for fibrotic scar treatment. J Tissue Eng Regen Med. 2017;11(11):3220–35.
pubmed: 28156060 pmcid: 5724515 doi: 10.1002/term.2213
Tonnard P, Verpaele A, Peeters G, Hamdi M, Cornelissen M, Declercq H. Nanofat grafting: basic research and clinical applications. Plast Reconstr Surg. 2013;132(4):1017–26.
pubmed: 23783059 doi: 10.1097/PRS.0b013e31829fe1b0
van Dongen JA, Getova V, Brouwer LA, Liguori GR, Sharma PK, Stevens HP, van der Lei B, Harmsen MC. Adipose tissue-derived extracellular matrix hydrogels as a release platform for secreted paracrine factors. J Tissue Eng Regen Med. 2019;13(6):973–85.
pubmed: 30808068 pmcid: 6593768 doi: 10.1002/term.2843
Hoerst K, van den Broek L, Sachse C, Klein O, von Fritschen U, Gibbs S, Hedtrich S. Regenerative potential of adipocytes in hypertrophic scars is mediated by myofibroblast reprogramming. J Mol Med. 2019;97(6):761–75.
pubmed: 30891616 doi: 10.1007/s00109-019-01772-2
Kruger MJ, Conradie MM, Conradie M, Van De Vyver M. ADSC-conditioned media elicit an ex vivo anti-inflammatory macrophage response. J Mol Endocrinol. 2018;61(4):173–84.
pubmed: 30038054 doi: 10.1530/JME-18-0078
Mou S, Zhou M, Li Y, Wang J, Yuan Q, Xiao P, Sun J, Wang Z. Extracellular vesicles from human adipose-derived stem cells for the improvement of angiogenesis and fat-grafting application. Plast Reconstr Surg. 2019;144(4):869–80.
pubmed: 31568294 doi: 10.1097/PRS.0000000000006046
Spiekman M, Przybyt E, Plantinga JA, Gibbs S, van der Berend L, Harmsen MC. Adipose tissue–derived stromal cells inhibit TGF-β1–induced differentiation of human dermal fibroblasts and keloid scar–derived fibroblasts in a paracrine fashion. Plast Reconstr Surg. 2014;134(4):699–712.
pubmed: 25357030 doi: 10.1097/PRS.0000000000000504
Mazini L, Ezzoubi M, Malka G. Overview of current adipose-derived stem cell (ADSCs) processing involved in therapeutic advancements: flow chart and regulation updates before and after COVID-19. Stem Cell Res Ther. 2021;12(1):1–17.
pubmed: 33397467 pmcid: 7781178 doi: 10.1186/s13287-020-02006-w
Desmouliére A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122(1):103–11.
pubmed: 8314838 doi: 10.1083/jcb.122.1.103
Darby IA, Zakuan N, Billet F, Desmoulière A. The myofibroblast, a key cell in normal and pathological tissue repair. Cell Mol Life Sci. 2016;73(6):1145–57.
pubmed: 26681260 doi: 10.1007/s00018-015-2110-0
Desmouléire A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 1995;146(1):56–66.
Aarabi S, Bhatt KA, Shi Y, Paterno J, Chang EI, Loh SA, Holmes JW, Longaker MT, Yee H, Gurtner GC. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J. 2007;21(12):3250–61.
pubmed: 17504973 doi: 10.1096/fj.07-8218com
Howard EW, Crider BJ, Updike DL, Bullen EC, Parks EE, Haaksma CJ, Sherry DM, Tomasek JJ. MMP-2 expression by fibroblasts is suppressed by the myofibroblast phenotype. Exp Cell Res. 2012;318(13):1542–53.
pubmed: 22449415 pmcid: 4164435 doi: 10.1016/j.yexcr.2012.03.007
Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-β1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 2002;39(2):258–63.
pubmed: 11847194 doi: 10.1161/hy0202.103268
Neves LMG, Wilgus TA, Bayat A. In vitro, ex vivo, and in vivo approaches for investigation of skin scarring: human and animal models. Adv Wound Care (New Rochelle). 2023;12(2):97–116.
pubmed: 34915768 doi: 10.1089/wound.2021.0139
Tai Y, Woods EL, Dally J, Kong D, Steadman R, Moseley R, Midgley AC. Myofibroblasts: function, formation, and scope of molecular therapies for skin fibrosis. Biomolecules. 2021;11(8):1–27.
doi: 10.3390/biom11081095
Bullock AJ, Higham MC, MacNeil S. Use of human fibroblasts in the development of a xenobiotic-free culture and delivery system for human keratinocytes. Tissue Eng. 2006;12(2):245–55.
pubmed: 16548683 doi: 10.1089/ten.2006.12.245
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2
pubmed: 11846609 doi: 10.1006/meth.2001.1262
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.
pubmed: 22743772 doi: 10.1038/nmeth.2019
Higginbotham S. Fat, fibroblasts, and fibrosis; how deposits of adipose tissue ameliorate dermal scarring. The University of Sheffield; 2022.
Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol. 2003;163(2):621–32.
pubmed: 12875981 pmcid: 1868195 doi: 10.1016/S0002-9440(10)63689-9
Sohn SH, Kim B, Sul HJ, Choi BY, Kim HS, Zang DY. Foretinib inhibits cancer stemness and gastric cancer cell proliferation by decreasing CD44 and c-MET signalling. Onco Targets Ther. 2020;13:1027–35.
pubmed: 32099405 pmcid: 7006849 doi: 10.2147/OTT.S226951
Ejaz A, Epperly MW, Hou W, Greenberger JS, Rubin JP. Adipose-derived stem cell therapy ameliorates ionizing irradiation fibrosis via hepatocyte growth factor-mediated transforming growth factor-β downregulation and recruitment of bone marrow cells. Stem Cells. 2019;37(6):791–802.
pubmed: 30861238 doi: 10.1002/stem.3000
Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EL, Boerner SA, LoRusso PM. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13):3507–16.
pubmed: 20472683 doi: 10.1158/1078-0432.CCR-10-0574
Liguori TTA, Liguori GR, Moreira LFP, Harmsen MC. Fibroblast growth factor-2, but not the adipose tissue-derived stromal cells secretome, inhibits TGF-β1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Sci Rep. 2018;8(1):1–10.
doi: 10.1038/s41598-018-34747-3
Evans RA, Tian YC, Steadman R, Phillips AO. TGF-β1-mediated fibroblast-myofibroblast terminal differentiation—the role of Smad proteins. Exp Cell Res. 2003;282(2):90–100.
pubmed: 12531695 doi: 10.1016/S0014-4827(02)00015-0
Dally J, Khan JS, Voisey A, Charalambous C, John HL, Woods EL, Steadman R, Moseley R, Midgley AC. Hepatocyte growth factor mediates enhanced wound healing responses and resistance to transforming growth factor-β1-driven myofibroblast differentiation in oral mucosal fibroblasts. Int J Mol Sci. 2017;18(9):1–15.
doi: 10.3390/ijms18091843
Hecker L, Jagirdar R, Jin T, Thannickal VJ. Reversible differentiation of myofibroblasts by MyoD. Exp Cell Res. 2011;317(13):1914–21.
pubmed: 21440539 pmcid: 3123424 doi: 10.1016/j.yexcr.2011.03.016
Kato K, Logsdon NJ, Shin YJ, Palumbo S, Knox A, Irish JD, Roundseville SP, Rummel SR, Mohamed M, Ahmad K, Trinh JM, Kurundkar D, Knox KS, Thannickal VJ, Hecker L. Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. Am J Respir Cell Mol Biol. 2020;62(5):633–44.
pubmed: 31962055 pmcid: 7193787 doi: 10.1165/rcmb.2019-0092OC
Plikus MV, Guerrero-juarez CF, Ito M, Li YR, Priya H, Zheng Y, Shao M, Gay DL, Ramos R, Hsi TC, Oh JW, Wang X, Ramirez A, Konopelski SE, Elzein A, Wang A, Supapannachart RJ, Lee H, Lim CH, Nace A, Guo A, Treffeisen E, Andl T, Ramirez RN, Murad R, Offermanns A, Metzger D, Chambon P, Widgerow AD, Tuan T, Mortazvi A, Gupta RK, Hamilton BA, Millar SE, Seale P, Pear WS, Lazar MA, Cotsarelis G. Regeneration of fat cells from myofibroblast during wound healing. Science. 2017;355(6326):748–52.
pubmed: 28059714 pmcid: 5464786 doi: 10.1126/science.aai8792
Moulin V, Larochelle S, Langlois C, Thibault I, Lopez-Vallé CA, Roy M. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol. 2004;198(3):350–8.
pubmed: 14755540 doi: 10.1002/jcp.10415
Fayzullin A, Ignatieva N, Zakharkina O, Tokarev M, Mudryak D, Khristidis Y, Balyasin M, Kurkov A, Churbanov S, Dyuzheva T, Timashev P, Guller A, Shekhter A. Modeling of old scars: histopathological, biochemical and thermal analysis of the scar tissue maturation. Biology. 2021;10(136):1–15.
Ma Y, Barnes SP, Chen YY, Moiemen NS, Lord JM, Sardeli AV. Influence of scar age, laser type and laser treatment intervals on adult burn scars: a systematic review and meta-analysis. PLoS ONE. 2023;18:1–16.
doi: 10.1371/journal.pone.0292097
Ţuţuianu R, Roşca AM, Florea G, Prună V, Iacomi DM, Rădulescu LA, Neagu TP, Lascăr I, Titorencu ID. Heterogeneity of human fibroblasts isolated from hypertrophic scar. Rom J Morphol Embryol. 2019;60(3):793–802.
pubmed: 31912089
Nedelec B, Shankowsky H, Scott GP, Ghahary A, Tredget EE. Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-α2b. Surgery. 2001;130(5):798–808.
pubmed: 11685189 doi: 10.1067/msy.2001.116453

Auteurs

S Higginbotham (S)

Department of Materials Science and Engineering, University of Sheffield, Sheffield, UK. samhigginbotham98@gmail.com.
School of Clinical Dentistry, University of Sheffield, Sheffield, UK. samhigginbotham98@gmail.com.
Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. samhigginbotham98@gmail.com.

V L Workman (VL)

Department of Materials Science and Engineering, University of Sheffield, Sheffield, UK.

A-V Giblin (AV)

Department of Plastic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

N H Green (NH)

Department of Materials Science and Engineering, University of Sheffield, Sheffield, UK.
INSIGNEO Institute for in silico Medicine, University of Sheffield, Sheffield, UK.

D W Lambert (DW)

School of Clinical Dentistry, University of Sheffield, Sheffield, UK.

V Hearnden (V)

Department of Materials Science and Engineering, University of Sheffield, Sheffield, UK.
INSIGNEO Institute for in silico Medicine, University of Sheffield, Sheffield, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH